Once PLK1 was overexpressed, human melanoma cells exhibited an attenuated response to Vemurafenib treatment (Figs 3D, 3E, and S3B), along with the increased expression of metastatic markers N-Cadherin and Vimentin (Fig 3F and 3G). Here, PLK1 is linked to melanoma.